anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One of the effective ways to increase the quality of care provided by nurses is humanistic practice ability. The presence of humanistic practice ability provides more realistic, human-centered nursing care, improves the quality of life of patients, and also positively affects health expenditures. The humanist approach is increasing its importance day by day in planning individual care, evaluating the outcomes of care practices, and health-promoting information programs. In this context, it is of great importance to develop the humanist practice skills, humanist nursing spirit, humanist clinical practices and humanist nursing education of nurses who are actively involved in ICUs, as in all areas of care practice. In developing nurses\' humanistic nursing behaviors, their level of knowledge and behavioral skills should first be revealed.

When the literature was examined, it was seen that there were studies examining the extent to which nurses experienced ethical problems and dilemmas during caregiving, their attitudes, and ethical decision-making processes. While studies on nurses\' ethical decision-making processes are important, it is thought that studies measuring their level of humanistic behavior will also contribute to nursing care. This research aims to show the effect of intensive care nurses\' ethical attitude levels on their ability to act humanistically. The research is original in that it combines ethical attitudes and humanistic behavior. It is anticipated that the research will contribute to nursing care and the knowledge base of the nursing profession.
Patients in the control group were not intervened by the researcher during the HD sessions. Before the first HD session started, the "Descriptive Characteristics Form" and "Trait Anxiety Scale" were performed by the researcher while the patients were in the waiting room. Then, in every three HD sessions for one week, when the patients went to their beds, their vital signs were measured and recorded on the "Vital Signs Monitoring Form" and the "State Anxiety Scale" was administered just before the HD treatment session was started. Then, the vital signs of the patients were measured and recorded on the "Vital Signs Monitoring Form" at the 30th minute, 1st, 2nd, 3rd hour of the HD session and immediately after the end of the HD session. At the same time, the "State Anxiety Scale" was performed again immediately after the end of the HD session. The patient was then transferred out of the unit.
Twenty patients with cirrhosis and functional renal impairment, defined by a serum creatinine greater than 1,2mg/dl, will be included. Patients will receive daily midodrine at a dose of 10mg tid and 40g of albumin at 15-day interval. The follow-up period will be of 12 weeks. In all patients, liver and renal function, and vasoactive hormones (plasma renin activity, aldosterone, noradrenaline, ADH, endothelin and anf)will be determined at baseline conditions. At this moment, glomerular filtration rate and renal plasma flow determined by isotopic techniques as ambulatory blood pressure monitoring through a 24-hour period will be performed too. All these determinations will be repeated at 4 and 12 weeks. During the study period, just before the albumin infusions, blood will be drawn for creatinine and electrolytes determinations and these will be recorded as well physical examination performed.
Immunogenic tumors can be controlled by tumor-reactive Tcells either directly or after checkpoint blockade. In the end, most tumors will develop mechanisms to escape immune control. One of such a mechanism is formed by the functional impairment of the intracellular peptide transporter TAP1/TAP2 by mutation of downregulated expression. As a result the presentation of conventional T-cell epitopes in HLA class I is lost, and hence tumor-reactive CD8+ T-cells fail to recognize and kill tumor cells. This type of immune escape can occur in up to 50% of primary tumors and is increased in the metastatic lesions of such tumors. The presence of these TAP defects correlate with worse clinicopathological parameters and has been associated with loss of durable benefit to checkpoint inhibition. The unmet need, therefore, is the development of a therapy that can reinforce effective tumor-immunity to cancers displaying TAP-defects for which conventional therapeutic cancer vaccines and/or checkpoint blockade do not work. TEIPP therapy may fill this position by reinstalling an effective antitumor response to TAP-defective tumors thereby increasing the overall survival of patients failing first line therapy.

In this prospective, single arm, multicenter, open-label, phase I-II clinical study, HLA-A\*0201-positive patients with NSCLC failing first line of treatment will be enrolled in 3 cohorts and one extension cohort of 6 patients (at the highest safe and tolerable dose) combined with a checkpoint inhibitor targeting PD-1/PD-L1 (CPI), to include 24 patients in total. The maximal total treatment duration is 9 weeks. The first 6 patients will be enrolled in cohort 1, the next 6 patients in cohort 2, the next 6 patients in cohort 3. The decision to start enrollment at the next dose level will be made by assessing the safety after 3 out of 6 patients at the previous dose level have completed vaccine therapy.

Patients will receive an off the shelf TEIPP24 vaccine mixed with Montanide ISA-51 adjuvant, which will be administered every three weeks for a period of three rounds of vaccination. Patient cohort 1 will be treated with TEIPP24 at a dose of 20ug of peptide, patients in cohort 2 with TEIPP24 at a dose of 40ug of peptide and patients in cohort 3 with TEIPP24 at a dose of 100ug of peptide. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI). Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in a limb. The SC route of administration of TEIPP24 vaccine is dictated by the use of Montanide ISA51. Subsequently patients will be followed up to 1 year after the first vaccination.
A system for determining the level of an analyte in a physiological fluid of a live individual is described. A wearable sensor periodically obtains data representative of the level of the analyte and has a passive RFID tag that stores the data. A receiver wirelessly interrogates the sensor with an RF interrogation signal. The RFID tag modulates or otherwise modifies the wireless interrogation signal using the data and the receiver receives back the modulated or otherwise modified interrogation signal and extracts the data from it. The receiver then determines, from the data, the level of the analyte in the fluid. The sensor may be a photometric or colorimetric sensor or an electrochemical sensor. The receiver may be, or be incorporated into, a hand-held device, a portable device, a PDA, a mobile telephone, or a laptop computer. The resulting system is more versatile and consumes less power than conventional systems.
To enhance user experience and improve patient workflow, data collection and patient imaging protocols are monitored, and real-time notifications are triggered, generated and provided to end users (e.g., radiologists, technicians, service personnel, hospital administrators, etc.) automatically, remotely, and in real-time when customizable conditions are met, such as a scan protocol is completed and reconstruction is successful. Notifications are sent from the scanner host computer or analysis system and received via email, instant message, etc., and may be pulled into a separate mobile application. A progress indicator is provided that facilitates informing an attending physician of the predicted scan completion time so that the physician may be immediately ready (e.g., to reach a viewing room, a scanning room, log on to a mobile viewing device, etc.) to view the scan results. The user may choose to view aborted, completed or ongoing scans of any patient, patient group, medical device, or any selected hospital.
This 5-year proposal responds to PAS-03-168, "Enrolling Women and Minorities in HIV/AIDS Research Trials." This study seeks to evaluate persuasive message interventions to increase HIV testing rates and improve acceptability of participation in a phase 3 HIV vaccine clinical trial among African-American, Latina, and White women. We plan to evaluate 1-sided messages, which mention only the benefits of an action, versus 2-sided messages, which mention negative aspects of the action, followed by positive counterarguments. The Health Belief Model, Inoculation and Attribution Theories will guide the research. Participants will be women attending urban community health clinics in Indianapolis, IN. Specific Aim 1 is to identify obstacles to HIV testing and to participation in a HIV vaccine clinical trial. This aim will be accomplished in years 1 and 2 through individual semi-structured interviews. We will analyze data via thematic content analysis and will use interview findings to assist in the development of measures and interventions employed in the intervention phase (years 3-5). Specific Aim 2 is to evaluate the effects of 2-sided versus 1-sided persuasive messages on rates of acceptance of rapid HIV testing. Demographic, behavioral, and attitudinal measures will be administered via audio computer-assisted self-interview (A-CASI). Participants will be randomized to the intervention groups via A-CASI as well. The outcome will be acceptance/rejection of free rapid HIV testing. This Aim will be evaluated via binary logistic regression. Specific Aim 3 is to evaluate the effects of 2-sided versus 1-sided messages on willingness to participate in phase 3 clinical trials for a preventive HIV vaccine. Participants will complete this 2nd A-CASI survey and will again be randomized to intervention groups. The outcome will be a scale measuring acceptability of clinical trial participation. This Aim will be evaluated via one-way Analysis of Variance. This study is relevant to public health in that the results may help us to understand how to improve enrollment of women and minorities into preventive HIV vaccine clinical trials and how to encourage women and minorities to get tested for HIV.
The invention provides an application of glabridin in preparing a medicament for treating colorectal cancer, belonging to the technical field of antitumor biological medicines. The inhibition activity of GBN on human colon cancer cells is verified by a CCK-8 method, and the survival rate is obviously reduced. The influence of GBN high and medium dose groups on apoptosis of human colon cancer cells is detected by adopting a flow cytometry technology, and the apoptosis rate is increased. The influence of GBN of 40 mug/mL on the cell migration of human colon cancer is researched through a cell scratch experiment, and the cell migration capacity can be obviously inhibited. The influence of GBN of 40 mug/mL on the invasion capacity of human colon cancer cells is researched through a Transwell experiment, and the number of invasion cells is obviously reduced. After GBN intervention is detected through a Western blotting experiment, the influence on the expression level of protein related to human colon cancer cell transfer invasion is obviously improved, and the expression levels of Bax, clear-caspase 3 and clear-caspase 9 proteins are obviously improved, so that the expression levels of Bcl-2 and MMP9 proteins are obviously reduced. GBN inhibits human colon cancer cell proliferation in vitro and induces tumor cell apoptosis, the mechanism of action of which may be related to inhibition of PI3K/AKT/mTOR signaling pathway.
Aortic stenosis (AS) and hypertrophic cardiomyopathy (HCM) are distinct disorders leading to left ventricular hypertrophy (LVH), but whether cardiac metabolism substantially differs between these in humans remains to be elucidated. We undertook an invasive (aortic root, coronary sinus) metabolic profiling in patients with severe AS and HCM in comparison with non-LVH controls to investigate cardiac fuel selection and metabolic remodeling. These patients were assessed under different physiological states (at rest, during stress induced by pacing). The identified changes in the metabolome were further validated by metabolomic and orthogonal transcriptomic analysis, in separately recruited patient cohorts. We identified a highly discriminant metabolomic signature in severe AS in all samples, regardless of sampling site, characterized by striking accumulation of long-chain acylcarnitines, intermediates of fatty acid transport across the inner mitochondrial membrane, and validated this in a separate cohort. Mechanistically, we identify a downregulation in the PPAR-α transcriptional network, including expression of genes regulating fatty acid oxidation (FAO). In silico modeling of β-oxidation demonstrated that flux could be inhibited by both the accumulation of fatty acids as a substrate for mitochondria and the accumulation of medium-chain carnitines which induce competitive inhibition of the acyl-CoA dehydrogenases. We present a comprehensive analysis of changes in the metabolic pathways (transcriptome to metabolome) in severe AS, and its comparison to HCM. Our results demonstrate a progressive impairment of β-oxidation from HCM to AS, particularly for FAO of long-chain fatty acids, and that the PPAR-α signaling network may be a specific metabolic therapeutic target in AS.
β3-Adrenergic receptor (β3AR) agonists have been shown to protect against ischemia-reperfusion injury (IRI). Since β3ARs are present both in cardiomyocytes and in endothelial cells, the cellular compartment responsible for this protection has remained unknown. Using transgenic mice constitutively expressing the human β3AR (hβ3AR) in cardiomyocytes or in the endothelium on a genetic background of null endogenous β3AR expression, we show that only cardiomyocyte expression protects against IRI (45 min ischemia followed by reperfusion over 24 h). Infarct size was also limited after ischemia-reperfusion in mice with cardiomyocyte hβ3AR overexpression on top of endogenous β3AR expression. hβ3AR overexpression in these mice reduced IRI-induced cardiac fibrosis and improved long-term left ventricular systolic function. Cardiomyocyte-specific β3AR overexpression resulted in a baseline remodeling of the mitochondrial network, characterized by upregulated mitochondrial biogenesis and a downregulation of mitochondrial quality control (mitophagy), resulting in elevated numbers of small mitochondria with a depressed capacity for the generation of reactive oxygen species but improved capacity for ATP generation. These processes precondition cardiomyocyte mitochondria to be more resistant to IRI. Upon reperfusion, hearts with hβ3AR overexpression display a restoration in the mitochondrial quality control and a rapid activation of antioxidant responses. Strong protection against IRI was also observed in mice infected with an adeno-associated virus (AAV) encoding hβ3AR under a cardiomyocyte-specific promoter. These results confirm the translational potential of increased cardiomyocyte β3AR expression, achieved either naturally through exercise or artificially through gene therapy approaches, to precondition the cardiomyocyte mitochondrial network to withstand future insults.
The control group was informed about self-management for 1 week. General information was given about approaches to improving self-management. Final evaluations were conducted for both groups after eight weeks.
Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
NEW MATERIAL:A human gp130 protein having the following properties. with affinity for complexes of interleukin-6 (IL-6) and an IL-6 receptor, exhibiting 130kDa apparent molecular weight in sodium dedecyl sulfate (SDS)- polyacrylamide gel electrophoresis and participating in signal transmission of the IL-6. USE:A reagent for developing therapeutic agent, etc., modulating the action of IL-6 PREPARATION:For example, an mRNA extracted from a human placenta according to a conventional method is used to prepare a cDNA library. A clone containing a DNA capable of coding gp130 protein is selected from the aforementioned library using a monoclonal antibody against the gp130. The DNA is then collected from the resultant clone, treated with a restriction enzyme, and linked to an expression vector to afford a recombinant DNA, which is subsequently transduced into a host cell. Transformation is carried out and the obtained transformed host cell is then cultured to afford the objective human gp130 protein.
Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. \[6-9\]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., \[6\].
At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up measures will be performed within a week after the end of the intervention, and 6 months thereafter, in order to examine long term effectiveness. Outcome measures are questionnaires; change will be assessed by the difference in total score between T1 \|(pre-intervention), T2 (post-intervention) and T3 (after 6 months)
A composition containing Pentaphylloides fruticosa extracts with anti-wrinkle and antioxidant activities is provided to show wrinkle and elasticity improvement by the Pentaphylloides fruticosa extracts having effects of inhibiting type I collagenase and AP-1 and increasing generation of collagen while suppressing decomposition of the collagen. A composition comprises Pentaphylloides fruticosa extracts obtained by adding water and alcohol or a mixed solvent thereof. The Pentaphylloides fruticosa has capability of eliminating radicals. The alcohol represents C1-C4 low alcohol such as ethanol and methanol. The composition containing Pentaphylloides fruticosa extracts is used for treating diseases caused by a large amount of accumulated active oxygen. The diseases caused by a large amount of accumulated active oxygen are liver disease, stroke, myocardial infarction, diabetic blood vessel disorder, hyperlipidemia, acute inflammation, rheumatic or cancer. The composition has a formulation of external skin application.
PURPOSE:To improve the rheology-controlling function by adding one or more kinds of alkyltrialkoxysiianes represented by specified formulae each in a prescribed amount to bentonite and bonding the alkylsilico groups to the surface of bentonite. CONSTITUTION:Bentonite is put in deionized water and dispersed with stirring. The obtained suspension is centrifuged and the resultant upper layer composed of a purified bentonite sol is evaporated to dryness so as to obtain anhydraus purified bentonite. 100 pts. wt. purified bentonite is charged into a pot mill and 1 to 10 pts. wt. alkyltrialkoxysilane expressed by formula [RSi(OR<1>)3] (R is a 1 to 22C saturated alkyl; R<1> is methyl, ethyl, propyl or butyl) is added thereto. The resultant mixture is then stirred and crushed in an anhydraus atmosphere so as to bond the alkylsilico groups to the partial surface of the bentonite. The obtained material is dispersed in water, thus obtaining the objective modified bentonite exhibiting a function for controlling rheology of an aqueous fluid. In addition, an organophilic modified bentonite can be obtained by further adding a quaternary ammonium cation thereto.
The invention provides a two-component drug delivery system for intravenous administration of an aqueous sterile acetylsalicylic acid composition comprising: a first and second components physically separated. The first component comprises a therapeutically effective amount of an acetylsalicylic acid and pharmaceutically acceptable excipients. The second component has a pH of 5,0 to 11,0 comprising an aqueous buffer solution and pharmaceutically acceptable excipients. The second component is selected for receipt of the therapeutically effective amount of acetylsalicylic acid and providing a buffered aqueous solution of acetylsalicylic acid with a pH of 6,0-8,0 upon mixing the first and second components. The components are sterile and the two-component drug delivery system provides a sterile buffered aqueous solution of acetylsalicylic acid upon mixing of said first and second components. The first component comprises a sterile spray dried or a sterile 20-90 kGy gamma irradiated, or an autoclaved terminally sterilized acetyl salicylic acid particulate powder.
Frailty is a major geriatric syndrome with a multifactorial etiology that induces a decline in multiple physiological and psychological functions. In traditional East Asian medicine (TEAM), qi and blood deficiency clinically represent as fatigue, anemia, anorexia, decreased strength after illness, and weakness, commonly interpretated as frailty. An herbal prescription of Insamyangyeongtang (IYT, Ninjin'yoeito in Japanese, Ren-Shen-Yang-Rong-Tang in Chinese) tonifies qi and blood and has the potential to treat multiple targets caused by qi and blood deficiency. As the population ages and frailty increases, there is an increase in the potential effectiveness of IYT in frailty. This study reviewed relevant clinical trials to provide an updated view on the effect of IYT on frailty. IYT has therapeutic effects on frailty associated with chronic respiratory diseases (e.g., chronic obstructive pulmonary disease) and cognitive impairments (e.g., Alzheimer's disease) and improves respiratory symptoms and cognition. IYT also has therapeutic effects on weight gain, muscle mass, and strength, and improves nutritional status in frail elderly individuals who have decreased muscle mass and strength, loss of appetite, and weight loss. The same effect has been shown in frailty in elderly individuals with rehabilitation treatment and chronic diseases. IYT also improves frailty associated with symptoms such as intractable dizziness and genitourinary symptoms. The beneficial effects of IYT in several diseases could be important for medication replacement, reduction, and prevention of polypharmacy. Based on the results of this review, we suggest that IYT has the potential to be a therapeutic agent against frailty.